4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 81 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,442,385 | -24.2% | 741,665 | +7.5% | 0.00% | 0.0% |
| Q2 2023 | $12,464,276 | +25.5% | 689,777 | +19.4% | 0.00% | 0.0% |
| Q1 2023 | $9,934,485 | +79528.8% | 577,922 | +2.9% | 0.00% | -50.0% |
| Q4 2022 | $12,476 | -99.7% | 561,737 | +6.2% | 0.00% | +100.0% |
| Q3 2022 | $4,252,000 | +23.6% | 528,936 | +7.3% | 0.00% | 0.0% |
| Q2 2022 | $3,439,000 | -52.5% | 492,825 | +3.0% | 0.00% | 0.0% |
| Q1 2022 | $7,236,000 | -31.6% | 478,623 | -0.8% | 0.00% | 0.0% |
| Q4 2021 | $10,584,000 | +14.7% | 482,437 | +41.0% | 0.00% | 0.0% |
| Q3 2021 | $9,229,000 | +129.0% | 342,218 | +104.4% | 0.00% | 0.0% |
| Q2 2021 | $4,031,000 | -36.5% | 167,434 | +14.4% | 0.00% | 0.0% |
| Q1 2021 | $6,346,000 | +1099.6% | 146,298 | +1044.7% | 0.00% | – |
| Q4 2020 | $529,000 | – | 12,780 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |